BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Britain Courts Anthropic Amid US Defense Department Dispute 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Dublin, Oct. 20, 2016 -- Research and Markets has announced the addition of the "The Overview of Biosimilar Market in Japan ver2016" report to their offering.
The reader will understand overall trend of Japanese biosimilar market. The report covers market situation, pipeline, major players, and challenges and forecast of this market.
The market size for generics in 2012 was about 551 billion JPY. This was about 9% of the prescription drugs market as a whole. The generics market is estimated to grow to around 778 billion JPY in 2016.
The market for biosimilars was 4.5 billion JPY in 2012. A total of only three products including human growth hormone and erythropoietin were on the market by 2012. The market is expected to reach over 26 billion JPY by 2016.
Key Topics Covered:
1. Summary
2. Definition of biosimilar
3. Related Pharmaceutical Affairs
4. Market Size
5. Market Trends
6. Biosimilar Sales Items and Main Development Items (As of 2015)
7. Trends for Major Companies
8. Daiichi Sankyo
9. Nichi-Iko
10. Sanwa Kagaku
11. Mochida Pharmaceutical
12. Nippon Kayaku
13. Kissei
14. Boehringer Ingelheim
15. Future Development
16. Challenges and Forecast for Biosimilars
For more information about this report visit http://www.researchandmarkets.com/research/hbs5t6/the_overview_of
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biosimilars and Biosuperiors
